Advesya to present two posters at #ASH24
Paris, France – Advesya, a company dedicated to developing novel therapies targeting IL-1RAP, announced that it will present two posters at the 66th American Society of Hematology (ASH) Annual Meeting, to be held in San Diego, California, from December 7 to 10, 2024. First Poster Presentation: Our collaborators at ALFA (Acute Leukemia French Association) will […]
ADV-101 Preclinical Efficacy in Esophageal Cancer Presented at #CamSOC2014
ADV-101: A Topoisomerase I Inhibitor ADC Targeting IL-1RAP Demonstrates Promising Efficacy in Preclinical Esophageal Cancer Models With an estimated 604,000 new cases diagnosed worldwide in 2020, Oesophageal cancer ranks as the seventh most common cancer globally and remains a challenging malignancy with poor prognosis. Chronic inflammation, driven by IL-1-related cytokines, plays a critical role in its […]
Advesya Granted EMA Clinical Trial Application (CTA) for CCTx-001
Advesya Granted EMA Clinical Trial Application (CTA) for CCTx-001, Its Lead Investigational Cell Therapy Asset Targeting IL-1RAP for the Treatment of Relapsed/Refractory Acute Myeloid Leukaemia Paris – July 29th 2024 – Advesya, a pioneering biopharma company focusing on targeting IL-1RAP for the treatment of difficult-to-treat cancers today announces that it has […]
CCTx-001, a first-in-class autologous anti-IL-1RAP CAR T-cell therapy for the treatment of relapsed / refractory AML
CCTx-001, A FIRST IN CLASS AUTOLOGOUS ANTI-IL-1RAP CAR T-CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY AML Topic: Acute myeloid leukemia – Biology & translational research Background: Relapsed/refractory acute myeloid leukaemia (r/AML) poses significant therapeutic challenges, necessitating novel treatment strategies. While allogeneic hematopoietic stem cell transplantation remains the only curative option, outcomes for r/r AML are […]
Abstract 6322: CCTx-001 CAR T-cells targeting the AML specific antigen IL-1RAP show robust pre-clinical anti-tumor efficacy
Abstract 6322: CCTx-001 CAR T-cells targeting the AML specific antigen IL-1RAP show robust pre-clinical anti-tumor efficacy Abstract Despite significant advancements in acute myeloid leukemia (AML) treatment, patients with relapsed/refractory (r/r) AML have limited therapeutic options. Novel approaches are urgently needed. CAR T-cell therapy has shown remarkable success in hematological malignancies. However, its application in AML […]
Abstract 2360: ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models
Abstract 2360: ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models Abstract Chronic inflammation is intricately linked to cancer development, and the IL-1 cytokine family stands out as pivotal regulators of inflammation. All the pro-inflammatory cytokines within the IL-1 family rely on a single co-receptor called IL-1RAP which therefore emerges as […]
Ksenija Pavletic’s interview on BFM Business France
Ksenija Pavletic’s interview on BFM Business France In an insightful TV interview, Advesya’s CEO, Ksenija Pavletic, details the company’s mission to transform cancer care. The company emphasized its advances in personalized CAR T-cell therapy for the treatment of AML (Acute Myeloid Leukemia). The discussion highlighted Advesya’s significant contributions to improving patient outcomes and advancing the […]
